Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Kristina M. Ilieva; Kristina M. Ilieva; Anthony Cheung; Anthony Cheung; Silvia Mele; Giulia Chiaruttini; Silvia Crescioli; Merope Griffin; Mano Nakamura; Mano Nakamura; James F. Spicer; Sophia Tsoka; Katie E. Lacy; Andrew N. J. Tutt; Andrew N. J. Tutt; Sophia N. Karagiannis; Sophia N. Karagiannis

doi:10.3389/fimmu.2017.01911

Frontiers in Immunology (Jan 2018)

Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types

Kristina M. Ilieva,
Kristina M. Ilieva,
Anthony Cheung,
Anthony Cheung,
Silvia Mele,
Giulia Chiaruttini,
Silvia Crescioli,
Merope Griffin,
Mano Nakamura,
Mano Nakamura,
James F. Spicer,
Sophia Tsoka,
Katie E. Lacy,
Andrew N. J. Tutt,
Andrew N. J. Tutt,
Sophia N. Karagiannis,
Sophia N. Karagiannis

Affiliations

Kristina M. Ilieva: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Kristina M. Ilieva: Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom
Anthony Cheung: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Anthony Cheung: Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom
Silvia Mele: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Giulia Chiaruttini: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Silvia Crescioli: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Merope Griffin: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Mano Nakamura: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Mano Nakamura: Department of Informatics, Faculty of Natural and Mathematical Sciences, King’s College London, London, United Kingdom
James F. Spicer: School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom
Sophia Tsoka: Department of Informatics, Faculty of Natural and Mathematical Sciences, King’s College London, London, United Kingdom
Katie E. Lacy: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Andrew N. J. Tutt: Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom
Andrew N. J. Tutt: Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom
Sophia N. Karagiannis: St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London & NIHR Biomedical Research Centre at Guy’s and St. Thomas’ Hospitals and King’s College London, Guy’s Hospital, London, United Kingdom
Sophia N. Karagiannis: Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Cancer Centre, London, United Kingdom

DOI: https://doi.org/10.3389/fimmu.2017.01911
Journal volume & issue: Vol. 8

Abstract

Read online

Overexpression of the chondroitin sulfate proteoglycan 4 (CSPG4) has been associated with the pathology of multiple types of such as melanoma, breast cancer, squamous cell carcinoma, mesothelioma, neuroblastoma, adult and pediatric sarcomas, and some hematological cancers. CSPG4 has been reported to exhibit a role in the growth and survival as well as in the spreading and metastasis of tumor cells. CSPG4 is overexpressed in several malignant diseases, while it is thought to have restricted and low expression in normal tissues. Thus, CSPG4 has become the target of numerous anticancer treatment approaches, including monoclonal antibody-based therapies. This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct antiproliferative/metastatic and immune activating mechanisms of action.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords